During the past decade, Baskent University Istanbul Hospital conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Baskent University Istanbul Hospital" are "Myelofibrosis" (2 trials), "Post Essential Thrombocythemia Myelofibrosis" (2 trials), "Post Polycythemia Vera Myelofibrosis" (2 trials) and "Primary Myelofibrosis" (2 trials). Many other conditions were trialed in "Baskent University Istanbul Hospital" in a lesser frequency.

Most popular intervention types in "Baskent University Istanbul Hospital" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "parsaclisib" (2 trials), "placebo" (2 trials) and "ruxolitinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Baskent University Istanbul Hospital" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Baskent University Istanbul Hospital". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Baskent University Istanbul Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Baskent University Istanbul Hospital, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".